Zobrazeno 1 - 2
of 2
pro vyhledávání: '"J. F. Muñoz Nuñez"'
Publikováno v:
Journal of Crohn's and Colitis. 17:i740-i741
Background Vedolizumab (VDZ) is a gut-selective, anti- lymphocyte trafficking drug inhibiting α4β7-integrin approved for treatment of moderately to severely Crohn's disease (CD) and ulcerative colitis (UC). Methods Medical charts from CD patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6d96828a927882b464f1c5be8d307a9
https://doi.org/10.1093/ecco-jcc/jjac190.0741
https://doi.org/10.1093/ecco-jcc/jjac190.0741
Autor:
Beatriz Sicilia, O. Merino Ochoa, C Gonzalez Muñoza, D Casas Deza, Matilde Navarro, Pedro Almela, E Sánchez Rodríguez, L J Lamuela Calvo, Elena Ricart, V J Morales Alvarado, Eduardo Doménech, J Guardiola Capo, Y Ber Nieto, J Garcia Alonso, B Caballo, S García López, Noemí Manceñido, M Dura Gil, J. F. Muñoz Nuñez, I Rodríguez Lago, C A Tardillo, J M Arbonés Mainar, R. Lorente Poyatos, S Riestra Menéndez, M I Calvo Moya, Laredo de la Torre, L De Castro Parga, M Rivero Tirado, A Gutiérrez Casbas, M Iborra Colomino, P Lopez Serrano, M. Barreiro De Acosta, M Calafat, M. Chaparro, Francisco Javier Bermejo, Lucía Márquez, M D Martín Arranz, Javier P. Gisbert, M Esteve, Luis Bujanda
Publikováno v:
Journal of Crohn's and Colitis. 15:S298-S299
Background Clinical trials and real-life studies with Ustekinumab in Crohn’s disease show its good efficacy and safety profile. However, there are hardly any data on elderly patients, who are excluded from these clinical trials. Our aim is to evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df46a00f131678225bc18a7da7d62023
https://doi.org/10.1093/ecco-jcc/jjab076.388
https://doi.org/10.1093/ecco-jcc/jjab076.388